Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.7952W HIGH $26.80
Volume
844.30 K
Value Traded
33.75 M
Short % Float
16.94%
Days to Cover
6.2
+25.19%Week
+17.68%1 Month
+21.45%3 Month
+137.56%6 Month
-14.1%5 Year
-14.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.54 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
1.37 B
Total Shares
35.73 M
Float Shares
30.64 M
Insiders
14.67%
Institutions
89.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
TRAX Catalyst Timeline
Dated clinical, regulatory and corporate events for First Tracks Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for First Tracks Biotherapeutics, Inc.
33Total events
18Upcoming
7Tier-1 (high impact)
2026 to 2028Coverage
Upcoming catalysts 2
Event history 13
▼Equity OfferingCorporate
Securities purchase agreement for $200 million private placement of common stock at $32.75 per share
▲Topline ReadoutANB033Clinical Data
Positive top-line results from Cohort 1 (gluten challenge) of ANB033 Phase 1b trial in celiac disease
celiac diseasesource ↗
▲Primary Endpoint MetANB033Clinical Data
ANB033 met key histologic efficacy endpoints (Vh:Cd, IEL density, VCIEL) and symptom endpoints vs placebo at Week 6
celiac diseasesource ↗
▲Safety Data UpdateANB033Clinical Data
ANB033 well tolerated with no safety signals observed to date in Cohort 1
celiac diseasesource ↗
▲Enrollment CompleteANB033Trial
Completed enrollment for Cohort 1 of Phase 1b ANB033 trial in celiac disease
celiac diseasesource ↗
▲Fast Track DesignationANB033Designation
FDA granted Fast Track designation for ANB033 for celiac disease
celiac diseasesource ↗
●Trial CompletionANB101Trial
Phase 1a trial in healthy volunteers completed
healthy volunteerssource ↗
●AcquiredCorporate
Separation of AnaptysBio and First Tracks Biotherapeutics completed on April 20, 2026
Past FDA Catalysts and PDUFA Decisions
How TRAX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-12 | ANB033 | Phase 1b topline data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every TRAX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ANB033 Fast Track | celiac disease | Phase 1b | 2026-10-12 | LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p =0.009); LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -20.03 placebo-adjusted delta (p <0.001); Prevented an increase in symptoms throughout the entire gluten challenge, with lower CDSD score on ANB033 vs. placebo that was statistically significant from the first dayRead More | First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Orwin John ADirector | Option | 1,300 17,995 held | $0.00 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TRAX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 3.1 % | 63.87 M | 3.17 M |
TRAX Institutional Ownership Trends
TRAX Short Interest
Shares sold short, counted twice a month.
16.94%
Short % of Float
of tradable shares sold short
5.2M
Shares Sold Short
+15.3% vs prior count
6.2 High
Days to Cover
trading days of normal volume to buy every short share back
838.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TRAX ranks across every disease it competes in
Competitive Position is a premium feature
See how TRAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTRAX News
-TRAX
Oct 15, 2026▲ +5.6%on this news· ran to +21% by day 3
First Tracks Biotherapeutics Announces $200 Million Private Placement
First Tracks Biotherapeutics has announced a private placement of 6,106,870 shares at $32.75 per share, aiming to raise approximately $200 million. The funds will be used for general corporate purposes, including the clinical development of its CD122 antagonist, ANB033. The private placement is expected to close on October 19, 2026, pending customary conditions.
Read more →-TRAX
Oct 12, 2026▲ +6.9%on this newsshared move
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
First Tracks Biotherapeutics announced positive top-line results for ANB033 in a Phase 1b trial for celiac disease. The treatment demonstrated significant protective effects against gluten-induced intestinal damage and symptoms during a gluten challenge. ANB033 was well tolerated, with no serious adverse events reported. The company plans to advance ANB033 into late-stage development in 2027.
Read more →-TRAX
Oct 11, 2026▲ +6.9%on this newsshared move
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
First Tracks Biotherapeutics will announce top-line data from Cohort 1 of its Phase 1b trial for ANB033, a CD122 antagonist targeting celiac disease, on October 12, 2026. The investor call will include a live webcast and a press release detailing the findings. The trial assesses the prevention of mucosal damage in patients.
Read more →-TRAX
Aug 26, 2026First Tracks Biotherapeutics Announces Participation in September Investor Conferences
First Tracks Biotherapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences. The events include the Wells Fargo Healthcare Conference, Citi's Biopharma Back to School Conference, and the Morgan Stanley Global Healthcare Conference. The executive team will engage in fireside chats and one-on-one meetings, providing investors with insights into the company's developments.
Read more →-TRAX
Aug 12, 2026First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
First Tracks Biotherapeutics announced its financial results for Q2 2026, highlighting the completion of enrollment for Cohort 1 of the Phase 1b trial of ANB033 in celiac disease. The FDA granted Fast Track designation for ANB033, with top-line data from Cohort 1 expected in Q4 2026. The company is also enrolling patients for a trial in eosinophilic esophagitis and plans to expand ANB033 into additional indications in 2027.
Read more →-TRAX
May 22, 2026First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - May 21, 2026
First Tracks Biotherapeutics, a clinical-stage biotech firm, announced its participation in several upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum. CEO Daniel Faga and other executives will represent the company. A live webcast of the presentations will be available, with replays accessible for 30 days.
Read more →-TRAX
May 21, 2026First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
First Tracks Biotherapeutics, a clinical-stage biotechnology firm, announced its participation in several upcoming investor conferences. CEO Daniel Faga and other executives will present at the 2026 Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum. The company focuses on developing antibody therapies for autoimmune and inflammatory diseases.
Read more →-TRAX
May 14, 2026First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
First Tracks Biotherapeutics, Inc., reported its financial results for the first quarter of 2026, highlighting a significant launch with $180 million in cash. The company aims to advance its lead candidate ANB033 through ongoing Phase 1b trials in celiac disease and eosinophilic esophagitis. It also received positive feedback from the FDA regarding the development pathway for rosnilimab in rheumatoid arthritis. However, the company recorded a net loss of $50.5 million, reflecting increased general administrative costs associated with its recent separation from AnaptysBio.
Read more →-TRAX
Apr 20, 2026First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
First Tracks Biotherapeutics has officially debuted on Nasdaq under the ticker symbol TRAX, launching as a clinical-stage biotech company focused on developing antibody therapeutics for autoimmune diseases. The company has announced a robust cash reserve of $180 million, which supports its initial programs, including ANB033 for celiac disease. Trading begins today, marking the company's emergence after distribution to AnaptysBio shareholders. First Tracks aims to make meaningful advancements in managing immune pathway-related diseases.
Read more →-TRAX
Mar 26, 2026On April 20, AnaptysBio, Inc. (Nasdaq: ANAB) ("Anaptys" or the "Company") is expected to spin off its biopharma operations as First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) ("First Tracks Bio").
AnaptysBio, Inc. has announced plans to separate its biopharma operations from its royalty assets, creating two publicly traded companies. The newly formed First Tracks Biotherapeutics, Inc. (TRAX) will handle the biopharma segment and is set to distribute shares to Anaptys shareholders in a tax-free spin-off. The distribution is scheduled for April 20, 2026, and existing shareholders will receive shares on a one-for-one basis for each share of Anaptys they hold. The spin-off aims to provide a focused operational strategy and is anticipated to attract investor interest.
Read more →About First Tracks Biotherapeutics, Inc.
Headquarters10770 WATERIDGE CIRCLE, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next TRAX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime